Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022.
Roche’s deep oncology pipeline is adding a drug candidate from Repare Therapeutics that works by interfering with a DNA repair mechanism of cancer cells. Repare receives $125 million up front and it retains the right to share in the development and commercialization of the drug, camonsertib.
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.